Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Designing synthetic antigens that reprogram allergic immune memory toward durable, healthy responses — moving precision allergy vaccines toward the clinic.
Developing novel multivalent small molecules that selectively silence or eliminate the autoantibody-producing B cells driving autoimmune disease.
Building a CHO cell surface display library of all human proteins to enable comprehensive, high-throughput autoantibody profiling across autoimmune diseases and vaccine responses.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Profiling deep immune changes before AAV relapse to identify predictive biomarkers and therapeutic targets for this difficult-to-manage autoimmune vasculitis.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
Uncovering the mechanisms by which inflammasomes drive aberrant inflammation in humans to identify new therapeutic targets for autoinflammatory diseases and sepsis.
